MRI-Compatible Pacemaker Approved
HealthDay - System designed to work with magnetic resonance imaging devices
The first heart pacemaker designed to be used safely during certain MRI exams has been approved by the U.S. Food and Drug Administration.
Up to now, patients with pacemakers have been advised not to have an MRI, which has the potential to interfere with a pacemaker's settings and may cause the wiring to overheat, the FDA said in a news release.
The Revo MRI SureScan Pacing System has a built-in function that's meant to be turned on before a person undergoes an MRI. Even with the newly approved device, however, an MRI can only be used on certain people, on certain parts of the body, and under the supervision of specially trained technicians, the agency said.
Of 211 people implanted with the device who had an MRI during clinical testing, none had MRI-related complications, the FDA said.
The Revo device is produced by Medtronic Inc., based in Mounds View, Minn.
Copyright © 2011 HealthDay. All rights reserved.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.
